TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed (clinically) with type 2 diabetes mellitus (T2D) for at least 1 year prior to screening.~* Have been treated with basal-bolus multiple daily injection (MDI) therapy for at least 90 days prior to screening including:~  * Basal insulin glargine U-100, in combination with bolus insulin analog (insulin lispro, insulin aspart, or insulin glulisine) with meals.~ * Participant must have been treated with the same type of allowed bolus insulin analog for at least 30 days prior to screening.~* Participants may be treated with up to 3 of the following oral antihyperglycemic medications (OAMs) for T2D in accordance with local regulations:~  1. Metformin~ 2. Dipeptidyl peptidase-4 (DPP-4) inhibitor~ 3. sodium glucose cotransporter 2 (SGLT2) inhibitor~ 4. oral glucagon-like peptide 1 (GLP-1) agonist~* Doses of OAMs are required to have been stable for at least 90 days prior to screening.~* Participants may be treated with injectable GLP-1 receptor agonist for T2D in accordance with local regulations. The GLP-1 receptor agonist dose is required to have been stable for at least 90 days prior to screening.~* Have an HbA1c value ≥7.5% and ≤10% according to the central laboratory at screening.~Exclusion Criteria:~* Have been diagnosed at any time with type 1 diabetes mellitus or latent autoimmune diabetes in adults.~* Have had any episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within 6 months prior to screening.~* Have had any episode of hyperglycemic hyperosmolar state or diabetic ketoacidosis within 6 months prior to screening.~* Have hypoglycemia unawareness as judged by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY900014 (Type: EXPERIMENTAL): LY900014 (100 units/milliliter (U/mL)) is a mealtime insulin administered subcutaneously (SC) 0-2 minutes prior to each meal in combination with insulin glargine (100 U/mL) SC as long-acting insulin. Mealtime (bolus) and long-acting (basal) insulin doses were titrated to achieve glucose targets during the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female individuals, ages 18 to 68.~* Subjects must meet current Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-V) criteria for alcohol use disorder; documented positive urine toxicology screen for alcohol at intake or collateral information from family members, significant others, room-mates etc., on recent use.~* Subject has voluntarily given informed consent and signed the informed consent document.~* Able to read English and complete study evaluations.~Exclusion Criteria:~* Women who are pregnant, or nursing or are of childbearing potential and not practicing an effective means of birth control.~* Meet current criteria for use disorder on another psychoactive substance, such as, heroin, amphetamines, hallucinogens/Phencyclidine (PCP), excluding alcohol and nicotine.~* Any current use of opiates or past history of opiate use disorder (assessed via urine toxicology and self report).~* Current use of any psychoactive drugs (urine toxicology), including anxiolytics, naltrexone or antabuse.~* Any psychotic disorder or current Axis I psychiatric symptoms requiring specific attention.~* Significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology which in the opinion of study physician would preclude patient from fully cooperating or be of potential harm during the course of the study.~* Hypotensive individuals with sitting blood pressure below 90/50 mmHG.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- patients receiving 300mg PREG (Type: ACTIVE_COMPARATOR): Patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.
- patients receiving 500mg PREG (Type: ACTIVE_COMPARATOR): Patients randomly assigned to receive 500mg of pregnenolone (PREG) daily.
- placebo (Type: PLACEBO_COMPARATOR): Patients randomly assigned to receive a placebo daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with complex vascular abnormalities to be threat by a systemic therapy~* Patients must have adequate liver function (LDL-cholesterol, triglycerides,...)~* Patients must have adequate organ function: neutrophils \>1500/mm³, Hb \> 8,0 g et platelets\> 50.000/mm³ (no platelets limits for the Kasabach Merritt syndrome)~* Patients must have adequate renal function(normal creatinin depending on the age), clearance \> 70 ml/min/1.73m² and Urin Protein Creatinine ratio \<0.3 g.~* Karnofsky or Landry \> 50~Exclusion Criteria:~* Dental equipments or prosthesis interfering onto a radiological examen~* Other uncontrolled medical condition (uncontrolled diabetes, hypertension...)~* Concomitant drugs such as inhibitors/inducers of cytochrome P450 3A4 (CYP3A4)~* Immunocompromised patients, including known seropositivity for HIV~* Digestive problems modifying the absorption of Rapamycin (gastric tube feeding accepted)~* Pregnant or nursing (lactating) women~* Prior treatment with phosphatidylinositol 3-kinase (PI3K) and/or mTOR inhibitors

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: EXPERIMENTAL): Seric level between 10 to 15 ng/ml Pills for the adults and liquid for the children. Twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 8 and 13 years of age; diagnosed as having ADHD; otherwise healthy;~Exclusion Criteria:~* significant sensory or neurological limitations, epilepsy, mental retardation, psychosis, or pervasive developmental disorder; medications with known central nervous system effects such as tranquilizers, antidepressants, stimulants (including methylphenidate and amphetamines), sedating antihistamines and some asthma medications and dietary supplements but vitamins

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: In Vitro Myometrial Contractions in Laboring and Non-laboring Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age 37-41 weeks~* Patients requiring primary or first repeat Cesarean section~* Cesarean section under spinal anesthesia~Exclusion Criteria:~* Patients who require general anesthesia~* Patient who had previous myometrial surgery or more than one previous Cesarean section~* Patients with placental anomalies~* Patients with multiple pregnancy (twins, etc.)

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment (Type: EXPERIMENTAL): All samples will undergo dose response treatment (increasing concentrations) of one of the four uterotonic drugs: oxytocin, ergonovine, prostaglandin F2alpha, or misoprostol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of VIS410 to Assess Safety and Pharmacokinetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~* Body mass index between 18 and 33 kg/m2, inclusive~* Normal labs~* Volunteers agree to use acceptable contraceptive measures~Exclusion Criteria:~* Prior receipt of antibody or biologic therapy~* History of cancer, heart disease, diabetes, respiratory condition (eg asthma), autoimmune disorder, blood dyscrasias~* Any chronic condition requiring daily prescription or over the counter medication~* History of a previous severe allergic reaction~* Drug or alcohol abuse within previous 12 months~* Positive serology for human immunodeficiency virus (HIV) antibody, hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg)~* Positive pregnancy test~* Breast feeding~* Positive drug or alcohol test at screening or check-in~* Receipt of licensed vaccine (within 30 days) or other investigational product within 30 days or 5 half-lives, whichever is longer, before study product administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- VIS410 (Type: EXPERIMENTAL): VIS410 administered as a single infusion with ascending dose-escalation ranging from 2 to 50 mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered as a single infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥ 18 years of age.~* For patients with metastatic basal cell carcinoma (BCC), histological confirmation of distant BCC metastasis (eg, lung, liver, lymph nodes, or bone), with metastatic disease that is Response Evaluation Criteria in Solid Tumors (RECIST) measurable using computed tomography (CT) or magnetic resonance imaging (MRI).~* For patients with locally advanced BCC, histologically confirmed disease that is considered to be inoperable.~* For patients with locally advanced BCC, radiotherapy must have been previously administered for their locally advanced BCC, unless radiotherapy is contraindicated or inappropriate. For patients whose locally advanced BCC has been irradiated, disease must have progressed after radiation.~* For women of childbearing potential, agreement to the use of two acceptable methods of contraception, including one barrier method, during the study and for 12 months after discontinuation of vismodegib (GDC-0449).~* For men with female partners of childbearing potential, agreement to use a latex condom, and to advise their female partner to use an additional method of contraception during the study and for 3 months after discontinuation of vismodegib.~Exclusion Criteria:~* Prior treatment with vismodegib or other Hedgehog pathway inhibitors.~* Pregnancy or lactation.~* Life expectancy of \< 12 weeks.~* Patients with superficial multifocal BCC who may be considered unresectable due to breadth of involvement.~* Concurrent non-protocol-specified anti-tumor therapy (eg, chemotherapy, other targeted therapy, radiation therapy, or photodynamic therapy).~* Recent, current, or planned participation in an experimental drug study.~* History of other malignancies within 3 years of the first day of treatment with vismodegib in this study (Day 1), except for tumors with a negligible risk for metastasis or death, such as adequately treated squamous-cell carcinoma of the skin, ductal carcinoma in situ of the breast, or carcinoma in situ of the cervix.~* Uncontrolled medical illnesses such as infection requiring treatment with intravenous antibiotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vismodegib 150 mg (Type: EXPERIMENTAL): Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atovaquone as Tumour HypOxia Modifier

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Suspected NSCLC considered suitable for surgical resection by the lung multidisciplinary team meeting (MDT).~2. At least one measurable lesion (greater than 2.5cm maximal length in any direction) that the investigators consider on routine imaging (CT or PET-CT scan performed in the 60 days prior to consent (older scans may be accepted at the discretion of the Chief Investigator providing the results remain clinically significant)) likely to contain regions of hypoxia.~3. Male or female, Age ≥ 18 years.~4. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2~5. The patient is willing and able to comply with the protocol, scheduled follow-up visits and examinations for the duration of the study.~6. Written (signed and dated) informed consent.~7. Haematological and biochemical indices within given ranges~Exclusion Criteria:~1. Previous systemic chemotherapy or biological therapy within 21 days of commencing atovaquone treatment.~2. Treatment with any other investigational agent, or participation in another interventional clinical trial within 28 days prior to enrolment.~3. Known previous adverse reaction to atovaquone or its excipients.~4. Active hepatitis, gallbladder disease or pancreatitis~5. Patients with impaired gastrointestinal (GI) function or GI disease that may significantly alter absorption of atovaquone.~6. Concurrent administration of contraindicated agents in the 14 days prior to starting atovaquone as outlined in section 9.4 and the current atovaquone Summary of Product Characteristics (SmPC).~7. Concurrent administration of warfarin in the 14 days prior to starting atovaquone.~8. Patients taking known inhibitors of the electron transport chain such as Metformin.~9. Other psychological, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results.~10. Patients who are known to be serologically positive for Hepatitis B, Hepatitis C or HIV (Hepatitis and HIV testing specifically for confirming eligibility for this trial are not required).~11. Pregnant or breast-feeding women or women of childbearing potential unless highly effective methods of contraception are used.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Atovaquone suspension, 750mg/5ml bd and 1000mg (6.25ml) bd for 7-17 days. Device: PET-CT, Device: DWI-MRI
- Cohort 2 (Type: NO_INTERVENTION): Device: PET-CT, Device: DWI-MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented clinical diagnosis and electrophysiological evidence of MMN~* Patients who have previously responded to intravenous immunoglobulin (IVIG) and have been on stable treatment with IVIG for at least 12 weeks prior to screening~* Patients treated with the equivalent of ≥0.4g/kg body weight (bw) IVIG per month~* Provision of informed consent by patient~Exclusion Criteria:~* Aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) concentration \>2.5 times the upper normal limit (UNL)~* Creatinine concentration \>1.5 times the UNL~* Known allergic reactions to blood products~* Any skin disease interfering with the assessment of injection site reactions~* Any other medical condition, which in the opinion of the investigator, might interfere with successful completion of the protocol~* Any condition likely to interfere with the evaluation of the study drug or satisfactory conduct of the trial~* Participation in a study with an investigational drug within three months prior to enrolment~* Patients treated with the equivalent of \>2.0g/kg bw IVIG per month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vivaglobin (Type: EXPERIMENTAL): Vivaglobin® is a 16% (160 mg/mL) liquid formulation of human normal immunoglobulin for subcutaneous infusion. Subjects will receive weekly infusions of Vivaglobin® at a weekly dosage calculated based on previous intravenous immunoglobulin treatment (between 0.1 to 0.5 g/kg body weight per week).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Extension to Study TRCA-301

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Completed the 12-week treatment period and attended the Week 12 Visit in the parent study TRCA-301.~* Blood bicarbonate level of \>= 12 mEq/L at the Week 12 Visit in the parent study TRCA-301.~Key Exclusion Criteria:~* Any level of low blood bicarbonate at the Week 12 Visit that, in the opinion of the Investigator, requires emergency intervention or evaluation for an acute acidotic process.~* Required dialysis for acute kidney injury or worsening CKD during the parent study TRCA-301.~* Planned initiation of renal replacement therapy within 6 months following study entry.~* History or current diagnosis of diabetic gastroparesis, bowel obstruction, swallowing disorders, severe gastrointestinal disorders, inflammatory bowel disease, major gastrointestinal surgery, or active gastric/duodenal ulcers.~* Serum calcium \<= 8.0 mg/dL at the Week 10 in the parent study TRCA-301.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- TRC101 (Type: EXPERIMENTAL): Administered once daily (QD) for 40 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Administered once daily (QD) for 40 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Breathing Event Detection by a Continuous Positive Airway Pressure Device to Clinical Polysomnography

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 21-75~2. Diagnosis of OSAHS with a baseline AHI ≥ 15 events/hr of sleep assessed January 01, 2007 or later~3. CPAP prescription of 8cm of H20 or higher~4. Able and willing to provide written informed consent~5. Native English speaker~Exclusion Criteria:~1. Participation in another interventional research study within the last 30 days~2. Major medical or psychiatric condition that would interfere with the demands of the study and adherence to PAP. Examples include unstable cardiovascular disease (Class III / IV CHF), neuromuscular disease, cancer, and renal failure.~3. Chronic respiratory failure or insufficiency with suspected or known neuromuscular disease, moderate or severe continuous positive airway pressure (COPD) or other pulmonary disorders, or any condition with an elevation of arterial carbon dioxide levels (\> 45 mmHg) while awake, or subjects requiring continuous oxygen therapy.~4. Surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days~5. Surgery at any time for the treatment of OSAHS such as uvulopalatopharyngoplasty (UPPP)~6. Presence of untreated or poorly managed,non-OSAHS related sleep disorders:~   1. moderate to severe periodic limb movements(≥ 30/hr with symptoms or arousals)~  2. arousals associated with periodic limb movements \> 10 per hour or~  3. anyone experiencing chronic and severe insomnia.~7. Consumption of ethanol immediately prior to the research PSG

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CPAP Device (Type: EXPERIMENTAL): Breathing event detection (AED) by the CPAP device will be compared to breathing event detection by a simultaneous PSG (manual PSG scoring).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete